Resmed Inc

Resmed Inc(RMD)股票分析

$238.970

-3.226 (-1.35%)收盤時

Loading chart…
最高
242.575
開盤
241.540
成交量加權均價
239.80
成交量
2.55M
市值
28.14B
最低
237.870
成交金額
610.71M
企業價值/稅息折舊攤銷前利潤(TTM)
15.49

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

AI 分析 of Resmed Inc (RMD)

買進

ResMed Inc. is a good buy right now due to its current price of $238.97 being below the analyst price targets of $262 and $267, indicating significant upside potential. The stock has shown a strong RSI of 72.818, suggesting bullish momentum, and a solid gross margin of 58.12%, indicating good profitability. However, the recent insider selling by the CEO, who sold nearly 5,000 shares, may raise concerns about future performance, which is a risk to consider.

分析師評級(10)

上檔空間 +23.03%
買進
4 買進
2 持有
4 賣出
目前: 238.97
最低
260.00
平均
294.00
最高
345.00

RBC Capital

2026-09-15

目標價

$262

優於大盤

Citi

2026-09-10

目標價

$240

中性

KeyBanc

2026-08-31

目標價

$267

增持

Rothschild & Co Redburn

2026-08-19

目標價

$230

中性

RBC Capital

2026-08-07

目標價

$244

Sector Perform

估值指標

Resmed Inc(RMD)目前預期本益比為 18.52,5 年平均預期本益比為 25.85。

預期本益比

合理
5 年均值 P/E
25.85
目前P/E
18.52
高估
34.14
低估
17.55

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
19.60
目前EV/EBITDA
15.49
高估
24.23
低估
14.97

預期股價營收比

合理
5 年均值 P/S
6.73
目前P/S
5.49
高估
8.04
低估
5.42

Alphio AI 對 RMD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%RMD

$284.42

情境價格

基

基準

基準 · 50%RMD

$251.26

情境價格

悲

悲觀

悲觀 · 25%RMD

$215.34

情境價格

持有 RMD 的大戶

W

Walter Scott & Partners Limited

+ 持有RMD

+6.20%

3個月報酬率

W

Welch & Forbes LLC

+ 持有RMD

+4.44%

3個月報酬率

A

American Capital Management, Inc.

+ 持有RMD

+1.32%

3個月報酬率

G

Giverny Capital Inc.

+ 持有RMD

+1.23%

3個月報酬率

T

The MassMutual Trust Company, F.S.B., Trust Investments

+ 持有RMD

+0.04%

3個月報酬率

I

Ilex Capital Partners (Uk) LLP

+ 持有RMD

-0.03%

3個月報酬率

事件時間軸

2026-09-01 (ET)

09:00:00

Resmed Completes Sale of MatrixCare to Frazier Healthcare

2026-08-06 (ET)

19:00:00

Stock Futures Mixed as Doximity Soars 83.93%

16:30:00

ResMed Increases Quarterly Dividend by 10% to 66 Cents

16:30:00

Resmed Reports Q4 Revenue of $1.46B

資訊

RMD 常見問題 —— 由 Alphio AI 解答

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ResMed Inc. is a good buy right now due to its current price of $238.97 being below the analyst price targets of $262 and $267, indicating significant upside potential. The stock has shown a strong RSI of 72.818, suggesting bullish momentum, and a solid gross margin of 58.12%, indicating good profitability. However, the recent insider selling by the CEO, who sold nearly 5,000 shares, may raise concerns about future performance, which is a risk to consider.

10 analysts cover RMD: 4 rate it Buy, 2 Hold and 4 Sell. The average price target is 294.00.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易